Yousif Matloub

2.6k total citations
48 papers, 1.3k citations indexed

About

Yousif Matloub is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Genetics. According to data from OpenAlex, Yousif Matloub has authored 48 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Public Health, Environmental and Occupational Health, 24 papers in Hematology and 17 papers in Genetics. Recurrent topics in Yousif Matloub's work include Acute Lymphoblastic Leukemia research (27 papers), Childhood Cancer Survivors' Quality of Life (17 papers) and Chronic Myeloid Leukemia Treatments (15 papers). Yousif Matloub is often cited by papers focused on Acute Lymphoblastic Leukemia research (27 papers), Childhood Cancer Survivors' Quality of Life (17 papers) and Chronic Myeloid Leukemia Treatments (15 papers). Yousif Matloub collaborates with scholars based in United States, France and Australia. Yousif Matloub's co-authors include Sanjay Ahuja, Rachel A. Egler, H. Jean Khoury, Linda C. Stork, Jörge E. Cortes, Nyla A. Heerema, Kimmo Porkka, Ronald Paquette, Andreas Hochhaus and Paul S. Gaynon and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Yousif Matloub

46 papers receiving 1.3k citations

Peers

Yousif Matloub
Comparison fields: 5 of 90
  • Hematology 667
  • Public Health, Environmental and Occupational Health 621
  • Pediatrics, Perinatology and Child Health 446
  • Genetics 444
  • Rheumatology 333
Replace Birgitte Lausen with:
Birgitte Lausen Denmark
A van der Does-van den Berg Netherlands
Karel Hählen Netherlands
Osborn B. Eden United Kingdom
Kazuko Hamamoto Japan
Anders Castor Sweden
Masahito Tsurusawa Japan
Mei La United States
G. Henze Germany
Clare J. Twist United States
Birgitte Lausen Denmark View profile →
Citations per field, relative to Yousif Matloub
Yousif Matloub · 1×
Citations per year, relative to Yousif Matloub
Yousif Matloub · 1×

Countries citing papers authored by Yousif Matloub

Since Specialization
Citations

This map shows the geographic impact of Yousif Matloub's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yousif Matloub with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yousif Matloub more than expected).

Fields of papers citing papers by Yousif Matloub

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yousif Matloub. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yousif Matloub. The network helps show where Yousif Matloub may publish in the future.

Co-authorship network of co-authors of Yousif Matloub

This figure shows the co-authorship network connecting the top 25 collaborators of Yousif Matloub. A scholar is included among the top collaborators of Yousif Matloub based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yousif Matloub. Yousif Matloub is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331
2021 ·Journal of Clinical Oncology ·Leonard A. Mattano, Meenakshi Devidas, Kelly W. Maloney, Cindy Wang, Alison M. Friedmann, Patrick J. Buckley, Michael J. Borowitz, Andrew J. Carroll, Julie M. Gastier‐Foster, Nyla A. Heerema, Nina S. Kadan‐Lottick, Yousif Matloub, David T. Marshall, Linda C. Stork, Mignon L. Loh, Elizabeth A. Raetz, Brent L. Wood, Stephen P. Hunger, William L. Carroll, Naomi Winick
22
2
Increased Toxicity Among Adolescents and Young Adults Compared with Children Hospitalized with Acute Lymphoblastic Leukemia at Children's Hospitals in the United States
2021 ·Journal of Adolescent and Young Adult Oncology ·Ajay Gupta, (unknown), (unknown), Mary Ann O’Riordan, Yousif Matloub, Sanjay Ahuja
8
3
Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children’s Oncology Group
2019 ·Blood Advances ·Yousif Matloub, Karen R. Rabin, Lingyun Ji, Meenakshi Devidas, Johann Hitzler, Xinxin Xu, Bruce Bostrom, Linda C. Stork, Naomi Winick, Julie M. Gastier‐Foster, Nyla A. Heerema, Eileen Stonerock, William L. Carroll, Stephen P. Hunger, Paul S. Gaynon
15
4
Increased Toxicity Among Adolescents and Young Adults Treated for Acute Lymphoblastic Leukemia at U.S. Children's Hospitals
2017 ·Blood ·Ajay Gupta, Yousif Matloub, (unknown), MaryAnn O’Riordan, Sanjay Ahuja
2
5
L-asparaginase in the treatment of patients with acute lymphoblastic leukemia
2016 ·Journal of Pharmacology and Pharmacotherapeutics ·Rachel A. Egler, Sanjay Ahuja, Yousif Matloub
200
6
Comparative Toxicity by Sex Among Children Treated for Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group
2015 ·Pediatric Blood & Cancer ·Kathleen Meeske, Lingyun Ji, David R. Freyer, Paul S. Gaynon, Kathleen S. Ruccione, Anna Butturini, Vassilios I. Avramis, Stuart E. Siegel, Yousif Matloub, Nita L. Seibel, Richard Sposto
29
7
Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children’s Oncology Group (COG) Study AALL0331
2014 ·Blood ·Leonard A. Mattano, Meenakshi Devidas, Alison M. Friedmann, Elizabeth A. Raetz, Mignon L. Loh, Patrick J. Buckley, Michael J. Borowitz, Andrew J. Carroll, Julie M. Gastier‐Foster, Nyla A. Heerema, Nina S. Kadan‐Lottick, Yousif Matloub, David T. Marshall, Linda C. Stork, Brent L. Wood, Naomi Winick, Stephen P. Hunger, William L. Carroll, Kelly W. Maloney
13
8
Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Children’s Oncology Group (COG) AALL0331
2013 ·Blood ·Kelly W. Maloney, Meenakshi Devidas, Leonard A. Mattano, Alison M. Friedmann, Patrick J. Buckley, Michael J. Borowitz, Andrew J. Carroll, Julie M. Gastier‐Foster, Nyla A. Heerema, Nina S. Kadan‐Lottick, Mignon L. Loh, Yousif Matloub, David T. Marshall, Linda C. Stork, Elizabeth A. Raetz, Brent L. Wood, Naomi Winick, Stephen P. Hunger, William L. Carroll
9
9
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
2010 ·Haematologica ·Neha Shah, D.-W. Kim, Hagop M. Kantarjian, P Rousselot, Pedro Enrique Dorlhiac Llacer, Alicia Enrico, Jorge Vela‐Ojeda, Richard T. Silver, H. Jean Khoury, Martin Müller, Alexandre Lambert, Yousif Matloub, Andreas Hochhaus
180
10
Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion
2009 ·Cancer ·Kimmo Porkka, H. Jean Khoury, Ronald Paquette, Yousif Matloub, (unknown), Jörge E. Cortes
110
11
Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C)
2008 ·Journal of Clinical Oncology ·Michael J. Mauro, Michele Baccarani, Francisco Cervantes, J. H. Lipton, Yousif Matloub, (unknown), Richard M. Stone
60
12
Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children’s Oncology Group Study 1991
2008 ·Blood ·Yousif Matloub, Bruce Bostrom, Stephen P. Hunger, Anne Angiolillo, Catherine Cole, Blythe Thomson, Meenakshi Devidas, Nyla A. Heerema, Mei La, Patrick J. Buckley, William L. Carroll, Naomi Winick, Harland N. Sather, James B. Nachman, Paul S. Gaynon
10
13
Outcomes for B-Precursor Patients in Legacy Children’s Cancer Group (CCG) and Pediatric Oncology Group (POG) Studies in Childhood Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group (COG) Report.
2007 ·Blood ·Paul S. Gaynon, Bruce Camitta, Yousif Matloub, Paul L. Martin, Naomi Winick, Nita L. Seibel, W. Paul Bowman, Harland N. Sather, Meenakshi Devidas, Stephen P. Hunger, William L. Carroll
1
14
Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group
2006 ·Blood ·Yousif Matloub
84
15
Detection of Central Nervous System Leukemia in Children with Acute Lymphoblastic Leukemia by Real-Time Polymerase Chain Reaction
2005 ·Journal of Molecular Diagnostics ·Sharon R. Pine, Changhong Yin, Yousif Matloub, Hatem E. Sabaawy, Claudio Sandoval, Oya Levendoglu‐Tugal, M. Fevzi Özkaynak, Somasundaram Jayabose
19
16
Staged informed consent for a randomized clinical trial in childhood leukemia: Impact on the consent process
2004 ·Pediatric Blood & Cancer ·Anne Angiolillo, (unknown), Eric Kodish, Beverly J. Lange, Robert B. Noll, Kathleen S. Ruccione, Yousif Matloub
40
17
Is There a Potential Role for Serum Cardiac Troponin I as a Marker for Myocardial Dysfunction in Pediatric Patients Receiving Anthracycline-Based Therapy? A Pilot Study
2001 ·Cancer Investigation ·Prasad Mathew, (unknown), K. T. Kip, Emel Bayar, Rama Jasty, Yousif Matloub, Dennis W. Raisch
30
18
Anterior mediastinal mass in childhood non-Hodgkin lymphoma: Dilemma of post-therapy imaging
2000 ·Medical and Pediatric Oncology ·Emel Bayar, Prasad Mathew, Rama Jasty, Yousif Matloub, Margaret G. Robinson
2
19
Pediatric Case of the Day
1999 ·Radiographics ·Robert J. Coombs, Emel Bayar, Yousif Matloub, Manuel E. Velasco
7
20
Severe aplastic anemia preceding acute lymphoblastic leukemia
1993 ·Cancer ·Yousif Matloub, Richard D. Brunning, Diane C. Arthur, Norma K.C. Ramsay
24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Birgitte Lausen Breakdown of academic impact, for papers by A van der Does-van den Berg Breakdown of academic impact, for papers by Karel Hählen Breakdown of academic impact, for papers by Osborn B. Eden Breakdown of academic impact, for papers by Kazuko Hamamoto Breakdown of academic impact, for papers by Anders Castor Breakdown of academic impact, for papers by Masahito Tsurusawa Breakdown of academic impact, for papers by Mei La Breakdown of academic impact, for papers by G. Henze Breakdown of academic impact, for papers by Clare J. Twist
Rankless by CCL
2026